Cyclerion stock cut in half after disappointing sickle cell trial results

The Cambridge biotech has stopped work on its sophomore drug after it exhibited a lackluster effect in a 70-person study.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.